Followers | 237 |
Posts | 10817 |
Boards Moderated | 0 |
Alias Born | 07/17/2006 |
Thursday, June 18, 2020 1:39:48 PM
This is probably the most important determinate of why Du was so wrong..In 2012 when ANCHOR was completed..Virtully everyone in the lipology field held tht trig lowering ALWAYS resulted in the LDL-C levels increasing..Here to fore Trigs had been considered a risk factor for CVD events.
http://epadruginitiative.com/press/fda-puts-patients-at-risk
FDA convened an Adcom which met on Oct 13 1013..The independent panel voted on the now famous Mary Parks question..The question asked was considering the ANCHOR trial results (in light of three other trig lowering trials [Thrive, ACCORD, and AIM-HIGH]..none of which showed convincing evidence that trig lowering lowered CVD event risk) were they the panelist confident Vascepa in the suggested dose lower CVD event. The panel said no..The ANCHOR trial was not designed or powered to answer whether the drug would lower events or save lives inn those with CVD..The FDA continued in a full sweep to declare they no longer considered elevated trigs a risk factor..A position held by the AHA the ADA and the NIH..They followed shortly by reneging on the SPA they had granted Amarin..On the flimsy basis that new scientific evidence indicated EPA's ability to lower CVD event risk was unlikely..Central to FDA's turn about was that trig lowering did indeed raise LDL-C and FDA held that only LDL-C was a legit bio marker for CVD event risk..
Such were the events leading to the R-I CVOT..
It is inappropriate to consider points of view in clinical situations such as the therapeutic benefits of N-3s or "Fish Oil." By Picking out one study which supports ones point of view, where there are literally hundreds of other trials, studies or paper that do not agree. This is the very worst kind of kind of Cherry picking..And is "Fake Science" or "Judge Du Science"..That does not in anyway indicate the overall opinion of the Medical field..The truth is there was no consensuses.At the time of MORI. MORI was not a KOL..The issues were controversial and still were until a short time ago..Nothing that MORI said or did had any effect in the time and place where he said or did it..
The general view (the most agreed on) at that time would have been high Trigs are a risk factor for CVD but lowering trigs raised LDL-C and this was confirmed (expected) by the Friedwald Equation and the clinical specialists who treated Atherosclerosis. And the benefits of trig lowering were not great enough to defray the risks of raising the LDL-C..
":>) JL
Recent AMRN News
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 12:00:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 09:31:21 PM
- Amarin Chairman & CEO Issue Letter to Shareholders • GlobeNewswire Inc. • 01/22/2024 12:30:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM